Skip to main content

Advertisement

SpringerLink
Log in

The burden of rheumatoid arthritis and access to treatment: uptake of new therapies

  • Original paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

This paper presents data on international differences in use of TNF inhibitors. It is part of a study on burden and cost of RA, access to new therapies and the role of HTA in determining access and cost-effectiveness. United States has the fastest most extensive use of the new drugs, about three times the average in the western European countries and Canada. Eastern and central European countries as well as Australia, South Africa and Turkey lag far behind. However, some smaller European countries, most notably Norway and Sweden have use of the new drugs not far behind the United States. While the income level of the country, and thus the health care expenditures per capita is a major factor for determining use in low and middle income countries, there are still considerable differences among countries with similar high total health care expenditures. Differences in prices are considerable between the US and Europe due to the changes in exchange rates between the US dollar and the Euro, but high and low use is not systematically related to differences in price.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14
Fig. 15
Fig. 16
Fig. 17
Fig. 18
Fig. 19
Fig. 20
Fig. 21
Fig. 22
Fig. 23
Fig. 24
Fig. 25
Fig. 26
Fig. 27
Fig. 28
Fig. 29
Fig. 30
Fig. 31
Fig. 32
Fig. 33
Fig. 34
Fig. 35
Fig. 36
Fig. 37
Fig. 38

Similar content being viewed by others

References

  1. Tugwell, P., Pincus, D., Yocum, D., et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 333, 137–141 (1995)

    Article  Google Scholar 

  2. Drosos, A., et al: Rheumatoid arthritis in Greek and British patients: A comparative clinical, radiologic, and serologic study. Arthritis Rheum 35, 745–748 (1992)

    Article  Google Scholar 

  3. Antoni, C., Maini, R., Grunke, M., et al: Cooperative of QoL in rheumatic disease: results of a survey among 6,000 patients across 11 European countries. Arthritis Rheum 46, ACR (abstract) (2002)

Download references

Conflict of interest statement

This study has been funded by unrestricted grant from F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Author information

Authors and Affiliations

  1. Department of Economics, Stockholm School of Economics, Stockholm, Sweden

    B. Jönsson

  2. Department of Orthopedics, University of Lund, Lund, Sweden

    G. Kobelt

  3. Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria

    J. Smolen

Authors
  1. B. Jönsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Kobelt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Smolen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Jönsson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jönsson, B., Kobelt, G. & Smolen, J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ 8 (Suppl 2), 61–86 (2008). https://doi.org/10.1007/s10198-007-0089-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-007-0089-7

Keywords

JEL Classification

Search

Navigation